News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Intratumoral, pembrolizumab and mRNA-2752 for high-risk Ductal Carcinoma In Situ
Jan 21, 2025, 05:12

Intratumoral, pembrolizumab and mRNA-2752 for high-risk Ductal Carcinoma In Situ

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:

“Intratumoral, pembrolizumab and mRNA-2752 for high-risk DCIS : Phase 1 nonrandomized trial

80% response rate
no major systemic toxicities
complete tumor resolution in some possible surgery reduction
Ongoing studies needed.”

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In SituA Phase 1 Nonrandomized Clinical Trial

Authors: Kirithiga Ramalingam, Rachel Woody, Alexa Glencer

Intratumoral, pembrolizumab and mRNA-2752 for high-risk Ductal Carcinoma In Situ

Alexa Glencer cancer Kirithiga Ramalingam Kristina Jankovic OncoDaily Oncology Rachel Woody
Special Coverage
Blog
Aug 8, 2025, 08:38
Liyana Rafeek: The Future of Lymphoma Care
Insight
Aug 8, 2025, 07:59
Adrian Pogacian: Fear Comes as Natural, But Hope is Learned!
Drugs
Aug 8, 2025, 07:08
Adagrasib (Krazati) Updates 2025: Uses in Cancer, Side Effects, Dosages, Expectations, and More
Career
Aug 8, 2025, 06:20
Joseph Contessa Selected as the Chair of Radiation Oncology at Rutgers Cancer Institute
Dialogues
Aug 8, 2025, 06:16
Accelerating Cancer Drug Development with AI: Interview with Dr. Jen-Tang (JT) Lu from Vysioneer
Blog
Aug 8, 2025, 06:08
Better-Targeted Therapies for Patients with Acute Myeloid Leukemia - IU Simon Comprehensive Cancer Center
Blog
Aug 8, 2025, 05:59
The Silver Jubilee of the Townsville to Cairns Bike Ride: Raising Funds for Childhood Cancer - Children's Cancer Institute
Insight
Aug 8, 2025, 05:47
FASCO 2025: 97 Voices, One Mission: Part 2
Science
Aug 8, 2025, 05:44
Yan Leyfman: Turning Paradoxical Biology Into Precision Immunotherapy Opportunities
Science
Aug 8, 2025, 05:01
Arndt Vogel: ESMO-MCBS 2.0 Scorecards for Hepatocellular Carcinoma
Oncolibrary
Aug 8, 2025, 03:13
CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment
Oncolibrary
Aug 8, 2025, 03:09
Immunotherapy for Cancer Success Rate: What Patients Need to Know in 2025